42754-69-8

Basic information

• Product Name: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-phenyl-
• Synonyms: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-phenyl-
• CAS NO: 42754-69-8
• Molecular Formula: C₁₁H₉N₅
• Molecular Weight: 211.22
• Mol File: 42754-69-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 350.8±52.0 °C(Predicted)
• Appearance: /
• Density: 1.51±0.1 g/cm3(Predicted)
• PKA: 11.84±0.20(Predicted)
• CAS DataBase Reference: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-phenyl-(42754-69-8)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-phenyl-(42754-69-8)

Safety Data

• Hazardous Substances Data: 42754-69-8(Hazardous Substances Data)

Usage

Chemical structure

A pyrazolo-pyrimidine derivative with a phenyl group attached to the third position of the pyrazole ring

Uses

Commonly used in pharmaceutical research and drug development for its potential therapeutic applications

Properties

Investigated for its anti-cancer, anti-inflammatory, and anti-fungal properties

Potential

Shows promise as a potential lead compound for the development of new drugs targeting various biological pathways.

Upstream product

• 151266-23-8 4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 
• 98-80-6 phenylboronic acid 
• 2380-63-4 4-Aminopyrazolo<3,4-d>pyrimidin 
• 98-88-4 benzoyl chloride 
• 5515-36-6 α-cyano-β-hydroxycinnamonitrile 
• 31646-28-3 4-((methylthio)(phenyl)methylene) morpholinium iodide 
• 111509-91-2 (α-morpholinobenzylidene)malononitrile 
• 2032-36-2 Thiobenzmorpholid 
• 42754-56-3 2-(methoxyphenylmethylene)malononitrile 
• 46177-21-3 2-benzoylmalononitrile 
• 77287-34-4 formamide 
• 42754-61-0 5-amino-3-phenyl-1H-pyrazole-4-carbonitrile 

Downstream Products

• 1286278-45-2 C₁₄H₁₁N₅ 
• 1286278-57-6 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-(4-chlorophenyl)ethanone 
• 1286278-58-7 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-phenylethanone 
• 1286278-59-8 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-p-tolylethanone 
• 1286278-60-1 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-1-(thiophen-2-yl)ethanone 
• 1286278-61-2 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-phenylacetamide 
• 1286278-62-3 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-fluorophenyl)acetamide 
• 1286278-63-4 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-N-(4-chlorophenyl)acetamide 
• 1286278-66-7 ethyl 2-(4-((4-amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)acetate 

Relevant articles and documents

Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1 H-pyrazolo[3,4- d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3 H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3KδInhibitor for the Treatment of Chronic Obstructive Pulmonary Disease

Accumulated pieces of evidence have shown that PI3Kδplays a critical role in chronic obstructive pulmonary disease (COPD). Using a fragment-hybrid approach, we discovered a potent and selective PI3Kδinhibitor (S)-18. In the biochemical assay, (S)-18 inhibits PI3Kδ(IC50 = 14 nM) with high selectivity over other class I PI3Ks (56～83 fold). (S)-18 also achieves good selectivity over other protein kinases in the kinome (S-score (35) = 0.015). In the cell, (S)-18 selectively and potently inhibits the PI3Kδ-mediated phosphorylation of AKT T308 but not other class I PI3K-mediated signaling. Additionally, (S)-18 exhibits no apparent inhibitory effect on CYP isoforms except for a moderate effect on CYP2C9. Furthermore, it shows no apparent inhibitory activity against hERG (IC50 > 10 μM). In vivo, (S)-18 displays favorable PK properties for inhaled delivery and improves lung function in a rodent model of pulmonary inflammation. These results suggest that (S)-18 might be a new potential therapeutic candidate for COPD.

1,2-DITHIOLANE COMPOUNDS USEFUL IN NEUROPROTECTION, AUTOIMMUNE AND CANCER DISEASES AND CONDITIONS

This invention provides confounds of the formula (I): wherein Y1, Y2 Z, X1, X2, and W are defined in the specification. These compounds are useful in the treatment of tyrosine kinases, MAPK signaling pathway kinases and Ρ13K/ΑΚΤ/mTor signaling pathway kinases-mediated diseases; or conditions, such as neurodegeneration, neuroprotection, cancer, autoimmune as well as other diseases and conditions associated with the modulation of tyrosine kinases selected from FYN, FYN Y531F, FLT3, FLT3 -ITD, BRK, ITK, FRK, BTK, BMX, SRC, FGR, YES1, LCK, HCK, RET, CSK, LYN, and ROSI; MAPK pathway kinases selected from ARAF, BRAE CRAP, ERK1 /2, MEK1, MEK2, MEK3, MEK4, MEK5. MEK6, and MEK7; and P13K/AKT/mTor pathway kinases: selected from mTor, P13K a, Ρ13Κ β, P13Kγ, and P13K δ.

Pyrazolo[3,4-d]pyrimidine analogues: Synthesis, characterization and their in vitro antiamoebic activity

Pyrazolo[3,4-d]pyrimidine analogues were synthesized by treating 3-phenyl-1H-pyrazolo[3,4-d]pyrimidine-4-amine with different sulfonyl chlorides and triethylamine in dry dichloromethane. The structure of all the compounds was elucidated by spectral data a